Zanubrutinib (Waldenström's macroglobulinemia (WM), first-line treatment for patients unsuitable for chemo-immunotherapy or patients ≥ 1 previous therapy)

Subject:

• Active Substance: Zanubrutinib
• Name: Brukinsa^®
• Therapeutic area: Waldenström's macroglobulinemia
• Pharmaceutical company: BeiGene Germany GmbH

Time table:

• Start: 15.12.2021
• Final decision by G-BA: 16.06.2022

Final decision:

• No additional benefit proved